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Use of complementary and alternative medicine (CAM; 補充與替代醫學 bǔ chong yǔ tì dai yı xue) in
Parkinson disease (PD) ranged 40e70%. The objective of this study was to determine the frequency, types
and factors associated with the use of CAM in Indian PD patients. PD patients, fulﬁlling UKPD-Society
brain-bank diagnostic-criteria, attending Movement-disorders clinic of a tertiary-care teaching hospi-
tal in India from 1st May to 15th December 2012 were enrolled. Information on socio-demographic,
clinical data and treatment along with factors (source of information, beneﬁts, harms, reason for use
and cost) associated with CAM use were recorded. Out of 233 consecutive PD patients, 106 (46%) used
CAM. Mean ± SD age of CAM users was 56 ± 11.2 years. Among CAM users, 72% were males, with mean
age-onset 49 ± 11.16 years (P ¼ 0.042) and 73% receiving levodopa therapy (p ¼ 0.006). Longer duration
PD, higher education (graduates and above), urban residence, and fairly good perceived health were
other factors seen among CAM users. Reasons for using CAM were ‘feel good factor’ (73%), 9% took CAM
due to side effects from allopathic-medicines. Commonly used CAM were Ayurvedic, homeopathic
medicines, and acupuncture (針灸 zhen jiǔ) [74/106 (70%)]. Median CAM cost in Indian Rupees (INR) was
1000/month (USD16, range: 0-400USD/month in year 2012). Almost half of PD patients use CAM. Three-
quarters of Indian CAM using PD patients believe that CAM is harmless, using it at a substantial cost.
CAM-users are educated, young, urban dwellers, longer duration PD and receiving levodopa. Commonly
used CAM was Ayurvedic, Homeopathic medicines and acupuncture.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Complementary and Alternative Medicine (CAM; 補充與替代醫
學 bǔ chong yǔ tì dai yı xue) are a group of management practices
that are not part of conventional western medicine.1 In US, 40% of
Parkinson's disease (PD) patients use some form of CAM during the
course of their illness,2 while in Korea, it is as high as 76%.3 Though
using it for long periods and with other medications, most patients
are not aware of possible adverse effects and potential drug in-
teractions with their use.4 Traditionally, CAM has been used by PD
patients in China, India and Amazon-region in the form of herbalsciences Center, Department
, New Delhi, Ansari nagar e
hari).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).preparations containing anticholinergics, levodopa and MAO-B
inhibitors.5 Different forms of CAM include ingestion or, applica-
tion of preparations on surface of body, activities of different
severity such as yoga, meditation, dance, music and exercise. Cur-
rent study was undertaken on Indian PD patients at a tertiary care
teaching hospital to determine frequency, types and factors asso-
ciated, along with beneﬁts, harms and cost of CAM in PD patients.
2. Material & methods
Consecutive PD patients, fulﬁlling UKPD-society brain-bank
clinical diagnostic criteria,6 attending Movement-disorders clinic
from 1st May 2012 to 15th December 2012 were enrolled after
obtaining institution's ethics committee approval and informed
consent. Information on socio-demographic and clinical data; cur-
rent treatment and beneﬁts of treatment were recorded. Levodopa
equivalent daily dose (LEDD) was calculated according to the con-
version factors of individual anti-parkinsonian drugs.7 The LEDDrsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
Table 1
Demographic proﬁle of PD patients included in the study.
Variables Levels Value n (%)
Gender Males 171 (73.4)
Females 62 (26.6)
Age; years. Mean ± SDa
(range)
57.30 ± 11.79
(24e85)
Age of PD onset; years.
Mean ± SD (range)
50 ± 11.33 (17e76)
Duration of PD; months.
Mean ± SD (range)
86 ± 63.82 (5e384)
Type of PD Tremor dominant 129 (55.4)
Akinetic e rigid
dominant
104 (44.6)
H and Y Stage;b n (%) 1.0 17 (10.9)
1.5 12 (7.7)
2.0 54 (34.6)
2.5 40 (25.6)
3.0 23 (14.7)
4.0 10 (6.4)
UPDRS-total;c mean ± SD
(range)
24.63 ± 11.60
(4e60)
LEDD (mg);d mean ± SD
(range)
753.5 ± 434.30
(100e2500)
Antiparkinsonian drugs;
n (%)
LD/CDe 147 (63.1)
Syncapone
(LD/CD/Entacom)f
53 (22.7)
Rasagiline 179 (76.8)
Pramipexole 108 (46.4)
Roperinole 75 (32.2)
Amantadine 109 (46.8)
a Standard deviation.
b Modiﬁed Hoehn & Yahr stage.
c Uniﬁed Parkinson's disease rating scale.
d Levodopa equivalent daily dose.
e Levodopa/Carbidopa.
f Levodopa þ Carbidopa þ Entacapone.
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(LD)  (multiply) 1, controlled release LD/carbidopa  0.75, Enta-
capone/Stalevo (LCE); LD  0.33, Duodopa; 1.11, Pramipexole (as
salt)100, Ropinirole;20, Rotigotine:30, Selegiline -Oral;10,
Selegiline-sublingual;80, Rasagiline;100, Amantadine;1,
Apomorphine;10.7 Use of CAM (補充與替代醫學 bǔ chong yǔ tì dai
yı xue) atleast once during the course of disease for atleast one
month was considered as CAM used. Other information collected
was about the source of information about CAM, any beneﬁt or
harm observed, reason for use and cost of therapy. Perceived effect
of CAM therapy was assessed using a four-graded Likert scale
(worsening ¼ 0, no improvement ¼ 1, mild to moderate
improvement ¼ 2, substantial improvement ¼ 3). Perceived health
was recorded by a ﬁve-grade Likert scale (very bad ¼ 0, bad ¼ 1,
fairly good ¼ 2, good ¼ 3, very good ¼ 4). Patients were assisted in
ﬁlling the format. UPDRS; Uniﬁed Parkinson's disease rating scale8
and modiﬁed Hoehn & Yahr (H&Y) stage9 of disease were also
noted.
3. Statistical analysis
Data was analyzed using SPSS 18.0v and STATA. Descriptive
statistics for all variables were obtained to characterize patients.
Chi-Square, t-test and ManneWhitney test assessed differences
between CAM users and non-users with respect to socio-
demographic and clinical characteristics. t-test and ANOVA were
used to asses difference between CAM users and non-users. Logistic
regression analysis was used to identify signiﬁcance of various
clinical and epidemiological factors among CAM users and non-
users. P-value of <0.05 was considered statistically signiﬁcant.
4. Results
Two hundred and thirty-three PD patients (171, 73.4%men) with
mean (SD) age: 57.30 (11.79) years (range 24e85 years), mean (SD)
age of onset of PD symptoms: 50 (11.33) years (range 17e76) were
enrolled. One hundred and six patients (46%) had used CAM (補充與
替代醫學 bǔ chong yǔ tì dai yı xue) at least once or using currently
for at least one month (Tables 1 and 2). Mean ± SD age of patients
who had used CAM was 56 ± 11.2 years (range 24e78). Seventy-six
of 106 PD patients (72%) were males. Mean age of disease onset of
PD among CAM users was younger (49 ± 11.16 years) versus non-
users of CAM (52 ± 11.34) years, (p ¼ 0.042). Mean LEDD was not
signiﬁcantly different in patients using CAM (787.65 ± 430.98,
range 100e2500 mg) vs. those not using CAM (724.54 ± 434.97,
range 30e2149 mg) (p ¼ 0.801) (Table 2). However, signiﬁcantly
higher numbers of CAM users were receiving LD (77; 73%,
p ¼ 0.006) as compared to non-CAM user (n ¼ 70; 55%). Longer
duration of symptoms of PD (i.e. more than 72months) (p¼ 0.001);
more years of education (i.e. graduates and above) (p ¼ 0.031),
urban residence (p ¼ 0.001), fairly good perceived health status
(p ¼ 0.001) were signiﬁcant variables associated with use of CAM
on bivariate as well as multivariate analysis (Table 2). Gender, PD
type (tremor dominant vs. akinetic-rigid type), initial and current
subjective response to LD therapy, H&Y stage of PD, distance of
patients' residence from our institute showed no signiﬁcant dif-
ference regarding use of CAM. Signiﬁcant difference in use of CAM
was observed with the higher UPDRS-motor score on bivariate
analysis (P ¼ 0.008; OR ¼ 1.044, 95% CI: 1.01e1.08). Optimum
sensitivity and speciﬁcity calculated by drawing Receiver Operating
Characteristic Curve (ROC), resulted in UPDRS-motor score cut off at
24 was associated with signiﬁcant use of CAM by 2.4 times
(P ¼ 0.012, OR ¼ 2.44 95% CI ¼ 1.20e4.97), suggesting that patients
with UPDRS score higher than 24 aremore likely to use CAM. Socio-
economic status did not determine use of CAM. Most commonsource of information about CAM was friends (38%) followed by
others (32%), which included promoters' advice. 66% patients re-
ported no beneﬁt with CAM and 10% reported harmful effect with
CAM (commonest being worsening of symptoms when taken alone
without allopathic medicines). Most common reason for taking
CAM was “feel good” factor, a belief that CAM will improve their
physical status (73%), followed by belief that CAM is harmless (9%).
Twenty-nine of 106 (28%) patients took CAM alone and 15 of these
29 (50%) took it in early stage of disease before start of allopathic
treatment. Nine of 106 (9%) patients took CAMwith a belief that use
of allopathic medicines is associated with side effects. In 74 of 106
(70%) patients, CAM included some form of oral medication/mas-
sage/special exercise or yogic postures; interventions (e.g.
acupuncture, reﬂexology etc.) in 7% and 23% took both oral prep-
aration as well as intervention (Fig. 1). Most common CAM oral
preparation was Ayurvedic followed by homeopathic medicines
(Fig. 2). Acupuncture was the most common CAM intervention
(Fig. 3). Mean and median cost of CAM in Indian Rupees (INR) was
2210 (~USD 44, calculated at rates operable in 2012) and 1000 per
month (~USD 16) respectively with range INR 0 to 25000.5. Discussion
Our study shows that CAM (補充與替代醫學 bǔ chong yǔ tì dai yı
xue) is quite a common modality of treatment among PD patients
attending our Movement Disorders clinics. About half (46%) of our
Indian PD patients report using it, which is similar to that observed
by other authors,2,3,10e12 being higher than reported in USA and
lower than reported in Korea. India being the seat of origin of Ay-
urveda, it was our belief that use of CAM would be higher in India.
Also, since per capita income and consequently paying capacity of
Table 2
Factors associated CAM; Bivariate & multivariate analysis.
Variables Levels CAM (n ¼ 106; 46%) No CAM (n ¼ 127; 54%) Bivariate analysis Multivariate analysis
p-value ORb 95% CIc p-value OR 95% CI
Age in years, mean ± SDa (range) 56 ± 11.2 (24e78) 58 ± 12 (33e85) 0.276
Gender Males, n (%) 76 (72) 95 (75) 0.285 0.853 0.48e1.53
Age onset PD in years,
mean ± SD (range)
49 ± 11.16 (17e76) 52 ± 11.34 (29e76) 0.042 0.976 0.95e0.99 0.048 0.968 0.94e1.00
Duration PD, months; n (%) <36 19 (18) 38 (30) 0.001 1 0.003 1
36e72 16 (15) 44 (35) 0.727 0.33e1.61 0.913 0.37e2.24
>72 71 (58) 45 (35) 3.156 1.62e6.14 3.081 1.48e6.43
PD type Tremor 56 (53) 73 (58) 0.477 0.828 0.49e1.39
Akinetic-rigid 50 (48) 54 (43) 1.00
dH & Y Stage, mean ± SD (range) 2.35 ± 0.79 (1e4) 2.18 ± 0.68 (1e4) 0.156 0.120 0.65e0.40
eUPDRS-III mean ± SD (range) 28 ± 11.73 (11e60) 22 ± 11.0 (4e59) 0.008 1.044 1.01e1.08
gLD/CD prescribed Yes 77 (73) 70 (55) 0.006 2.162 1.25e3.75
No 29 (27) 57 (45)
LD Dose; mg/day in-group, n (%) <250 14 (20) 18 (23) 0.801
250e400 30 (43) 27 (35)
400e600 13 (19) 15 (20)
>600 13 (19) 17 (22)
fLEDD; mean ± SD (range) 787.7 ± 431 (100e2500) 724.5 ± 435 (30e2149) 0.174
Initial LD response >70% 63 (59) 63 (50) 0.532
25-69% 22 (21) 37 (29)
<25% 8 (8) 7 (6)
No response 5 (5) 5 (3)
Cannot qualify 8 (8) 15 (12)
Current LD response >70% 45 (43) 51 (40) 0.736
25e69% 34 (32) 44 (35)
<25% 12 (11) 11 (9)
No response 7 (7) 6 (5)
Cannot qualify 8 (8) 15 (12)
Perceived health, n (%) Quite bad 7 (7) 1 (1) 0.001 <0.001 1
Bad 19 (14) 16 (13) 0.424 0.390 0.04e3.91
Fairly good 62 (59) 59 (47) 0.199 0.234 0.03e2.15
Good 18 (17) 51 (41) 0.017 0.004 0.01e0.61
Education Illiterate 4 (3.8) 11 (8.7) 0.002 1 0.006 1
<X std. 13 (12) 36 (28) 0.992 0.993 0.27e3.67 0.985 1.014 0.24e4.25
X/XII std. 31 (29) 38 (30) 0.201 2.243 0.65e7.74 0.315 0.205 0.52e7.76
>Graduate 58 (55) 44 (33) 0.031 3.798 1.13e12.75 0.040 0.049 1.07e15.35
Distance from hospital, hKm; n (%) <100 62 (58) 83 (65) 0.254
100e200 15 (14) 9 (7)
200e500 10 (9) 16 (13)
>500 19 (18) 19 (15)
Location, n(%) Rural 5 (4.7) 24 (19) 0.001 1.00 0.011 1.00
Urban 101 (95) 103 (81) 0.002 4.707 1.73e12.82 4.119 1.38e12.29
Bold values are the values which are statistically signiﬁcant.
a Standard deviation.
b Odds ratio.
c conﬁdence interval.
d modiﬁed Hoehn & Yahr stage.
e Uniﬁed Parkinson's disease rating scale.
f Levodopa equivalent daily dose.
g Levodopa/Carbidopa.
h Kilometer.
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that CAM being less expensive and easily available would be
practiced bymore Indian PD patients as compared to PD patients in
USA and European countries. However this systematic study
showed results contrary to our belief. Our own results in Indian PD
patients showed that, more educated, those residing in urban
setting, individuals who have better access to information, more
knowledge, higher paying capacity and higher education level use
CAM more often.
Variables in disease proﬁle, which showed association with
CAM use, were younger age of symptom onset, longer disease
duration, higher baseline UPDRS motor score, fairly good perceived
subjective health and use of L-dopa. Socio-demographic factors
associated with CAM use were higher education status (more than
graduation) and urban living. These all variables showed overallpredictor accuracy of use of CAM as 75.27% (or factors were
correctly classiﬁed in 75.27%) excluded patients having higher
baseline UPDRSmotor score, fairly good perceived health and using
L-dopa (Fig. 4). In earlier studies, use of complementary therapy for
PD correlated signiﬁcantly with younger age of onset of symp-
toms.2,13 Longer disease duration was also associated with higher
CAM use, similar observation was made in previous studies.3,12
Another study from Singapore comprising of 159 PD patients,
observed rate of starting CAM was 1.2/100 person months. At 3
years after the diagnosis of PD, 48% of participants were using CAM,
at 5 years 62% and by 10 years 75% had started using CAM. Median
time of starting CAM in PD was 38 months (95% CI: 25e51).11
Relationship with duration of disease and CAM use has not been
observed bymany authors.2,11 PD patients with highermean UPDRS
motor score, suggesting severe/advanced disease was more often
Fig. 1. CAM (補充與替代醫學 bǔ chong yǔ tì dai yı xue) modalities (n, percentage of
CAM modalities).
Fig. 3. CAM* interventions (n, percentage of CAM modalities). * Complementary and
Alternative Medicines.
Fig. 4. ROC of signiﬁcant factors*. Area under ROC (Receiver Operating Characteristic
Curve) curve ¼ 0.8117, Correctly classiﬁed ¼ 75.27%. * Factors included for ROC curve
are: Age of onset, duration of PD, education status, residence of patients (urban or
rural).
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ported by previous study, which showed 2.5 times greater risk for
CAM use among participants with higher baseline motor score
(P ¼ 0.031; 95% CI: 1.1e5.8).11 However, in that study the cut off
UPDRSwas 16, while among Indian PD patients it was much higher,
that is 24. UPDRS-motor score of 24 or above was associated with
2.44 times higher risk of use of CAM, suggesting that Indian PD
patients probably can enduremore disability before they seek CAM.
In our cohort, there was one patient with UPDRS of 37 whowas not
taking any treatment at all, further supporting our belief. We did
not ﬁnd CAM use having any relation with other parameter of
disease severity such as H&Y stage as observed by other au-
thors.2,3,10 We did not ﬁnd any gender preference for use of CAM,
although other authors12,14 observed females used CAMmore often
than males.
Interestingly our study showed that PD patients who were
prescribed L-dopa used CAM more often than those who were not
prescribed L-dopa. Probable reason for this is that those in whom L-
dopa was started had more advanced disease requiring higher
dopa-agonist drugs dose/L-dopa to treat symptoms of PD. Though
use of L-dopa was associated with higher risk of CAM use, its dose
did not inﬂuence use of CAM. This observationwas at variance with
other studies.3,12 Mean LEDD did not differ between CAM users and
non-users in our study. Generally, Indian patients receive lower
mean LD dose and LEDD as compared to various other cohorts.3,12
This may be because Indian PD patients have lower body weight
or they are cautious about side effects of drugs and are reluctant to
increase drug dose.
Better subjective perception of health status among CAM users
was observed in our study. This is in difference from observation of
other authors. One study from Sweden, although not included PD
patients, reported that chronically ill patients used CAM more
often.15 In another study patients who perceived poor subjective
health status, used CAM more often.12 We believe our observation
can possibly be explained as follows: people, who have positive
attitude towards life, perceive their health as “good” even though
they may be having more advanced/severe disease and try allFig. 2. CAM* drugs (n, percentage of CAM modalitiemodalities that may be available for improving their status further,
including CAM. We can only contemplate on this aspect, since we
did not study personality trait of our patients. Higher use of CAM
among PD patients with higher education and urban living possibly
supports the hypothesis that availability of information/knowledge
through magazines, Internet/television and easy access to these are
reasons for higher use in these patients. In our study, PD patients
with higher education level i.e. graduation or more were more
likely to use CAM, which is an observation similar to other
studies.2,12,13 In a Swedish population-based study on patients with
cardiovascular disease, 30.5% reported CAM use in the preceding 2
weeks observed CAM use more frequently in persons with highers). * Complementary and Alternative Medicines.
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in urban set-up use CAM more often because they have access and
competency to utilize all possible sources of therapy. According to a
telephone survey in USA, 43% of general population had used CAM
during the previous year.17 A survey done on 1001 random sample
in Sweden found 49% of population surveyed were CAM users, as
compared to 34% from Norway and 45% in Denmark.14
Socioeconomic status did not determine use of CAM among PD
patients in our study, which is not in agreement with observation of
other.2,13 Possibly, in India many different types of CAM are easily
available at affordable cost. Paucity of Neurologists and low ratio of
neurologist to general population results in non availability of
neurologists to a large number of population, forcing most PD pa-
tients to seek other options, which may be easily available.
Most common source of information was friends followed by
others, which included promoters' advice as seen on television and
Internet. This suggests availability of information to PD patients
with higher education and living in urban setup. Majority of CAM
users did not obtain any beneﬁt from it (66%) while 10% addition-
ally reported harms with CAM use (most common being worsening
of symptoms when taken alone without allopathic medicines),
possibly because of progression of symptoms due to progressive
nature of disease. However we cannot rule out the beneﬁts or
harms of CAM on the basis of this cross sectional study. Large
randomized trial (well designed and well deﬁned homogenous
intervention of CAM) is required to see the beneﬁts or harms of
CAM on PD patients. Most common reason for taking CAMwas feel
good factor (73%), a belief that CAM will improve their physical
status followed by belief that CAM is harmless (9%). ‘Feel good
factor’ is awidespread feeling of well-being and ﬁnancial security.18
Many patients considered ‘Feel good factor’ as a feeling of general
well being that makes people feel happy and positive about their
lives, and that the intervention will do them good. Twenty-nine of
106 (28%) patients used CAM alone and 15 of these 29 (50%) took it
before start of allopathic treatment, while 9 of 106 (9%) took CAM
due to side effects from allopathic medicines. It is often believed
that CAM including Ayurvedic medicines etc. does not have any
side effects; therefore many patients try these without informing
their physicians.
Seventy percent of CAM included some form of drugs (Fig. 1);
like Ayurvedic (majority) and homeopathic medicine. Other forms
of CAM drugs used are as mentioned in Fig. 2, few could identify
these Ayurvedic medicine as powder of seeds of Macuna pruriens
commercially available in India, ‘Ashwagandha’, ‘panchkarma’,
‘Brahmi’, ‘Jeeva mala’, Kampavatras', ‘Mochpak’, ‘Swarasta rist’, ‘Til
oil’, ‘Nutralite’. Powder of dried seeds of Macuna pruriens is a
natural sources of levodopa, Macuna Pruriens and ‘Vicia faba’ have
been studied in small randomized trials but neither has been tested
formally against conventional levodopa in randomized blinded
trials to show its equivalence, superiority/inferiority or compara-
tive study of side effects.19,20 ‘Ashwagandha’ (herb; Withania
somnifera, family Solanaceae) Sitoindosides, Withaferin-A and
acyl-steryl-glucosides in Ashwagandha and ‘Brahmi’ an herb from
Bacopa Monnieri family: (scrophulariaceae, water hyssop.) have
been used in PD and other neurodegenerative disorders.21,22 ‘Pan-
chkarma’; consisting of ﬁve types of therapeutic measures/activ-
ities.23 ‘Til oil’ or Sesame seed oil is one of the common edible oil in
India and in other Asian countries; a study has evaluated its neu-
roprotective effect in PD mice model and shows a good neuro-
protective and anti-inﬂammatory beneﬁt.24 Another modality is
herbal medicines such as ‘Aloevera juice’ (Ayurvedic Miracle Plant),
‘Wheat grass’, ‘Amla (India gooseberry) juice’, ‘Balwach’, ‘Sumanta’.
Aloe Vera Barbadenis, is used for therapy in formulations as
external application or oral use ‘Aloe vera’ leaves contain 96% water
and also Vitamins A, B, C, E, calcium, amino acids etc. ‘Amla juice’ orIndian gooseberry (Phyllanthus emblica or Emblica ofﬁcinalis (油柑
You Gan)) is rich in vitamin C and is extensively used in Ayurveda.
One unusual CAM was oral consumption of placental cord blood
reported by one PD patient. Among interventions (Figs. 1 and 3),
acupuncture (48%) was the most commonly utilized and other re-
ported interventions were ‘Yoga’, ‘Massage’, ‘Mud application’ over
whole body, Transcutaneous electric nerve stimulation’ (TENS),
‘Magnet therapy’, ‘Cow dung’ application over whole body, foot
reﬂexology and music therapy. Twenty-one percent of PD patients
took both CAM drugs and interventions.
Mean and median cost of CAM per month was INR 2211
(~USD36, in 2012) and 1000 (~USD16) per month respectively
(range INR 0e25000), whereas the mean ± SD per capita income
permonth of our study cohort was INR 12,202.70 ± 9073 (range INR
1200e50000). According to Indian government sources per capita
income of an Indian at current price was INR 53,331/year in
2011e12 which makes per capita income per month as INR
4,444.25.25 It appears our study population had higher per capita
income per month in comparison to average Indian. Our PD cohort
used almost 20e40% of their monthly income on CAM. It is to be
noted that for most Indian patients treatment cost is not reim-
bursed and must be borne by the individual.
There are many gray areas in CAM; lack of randomized double
blind trials published in peer reviewed journals, as well as het-
erogeneity of products and practices. Due to relatively high prev-
alence of CAM use in our study and in others, physicians should
routinely enquire patients about CAM, as its use could increase risk
of unwanted side effects, drug interactions, contamination of CAM
with other agents, or trauma inﬂicted by inexperienced CAM
practitioners. Once informed, physicians should respect patient's
beliefs, perspectives, and cultural practices, and be open-minded
about evaluating CAM treatment together with them. This raises
ethical and professional problems as physician has a responsibility
to ensure that patients' management is safe and in agreement with
scientiﬁc tenets.26 To assure effect of CAM, it is important to have
objective means of rating patients' state before and after treat-
ment.27 Thus, there is a need for evidence-based effectiveness and
safety information about CAM therapies, together with respect for
patients' beliefs and choices.
6. Limitations
Concerning the functional outcome after use of CAM (補充與替
代醫學 bǔ chong yǔ tì dai yı xue) is not observed using objective
scales and also we did not follow up patients for a signiﬁcant longer
duration to assess any form of beneﬁts or harms related to CAM.
Also there is large diversity of CAM therapeutic interventions in this
study, and not clearly deﬁned. Also this cross sectional survey was
not designed to speciﬁcally study the prevalence of use of Ayurveda
but all the complementary and alternative medicines in Indian PD
patients. This is the limitation of the study that various subtypes of
Ayurveda treatment have not been studied. Duration of the CAM
treatment has not been investigated. It needs a well-designed
randomized study with well-deﬁned homogenous intervention of
CAM.
7. Conclusion
Forty-six percent of Indian PD patients attending a tertiary care
teaching hospital in India use CAM (補充與替代醫學 bǔ chong yǔ tì
dai yı xue). Most commonly used CAM is Ayurveda therapy. Early
age at symptom onset, longer duration of illness, urban residence,
higher education status, fairly good perceived subjective health,
higher disease severity (UPDRS-motor score), and levodopa use, are
associated with higher use of CAM. However, levodopa dose and
A.K. Pandit et al. / Journal of Traditional and Complementary Medicine 6 (2016) 377e382382LEDD did not inﬂuence use of CAM. Many PD patients reported no
beneﬁts with CAM in this cross sectional study; however, it needs
to be conﬁrmed in large well-designed randomized trials. Median
expense of CAM in Indian Rupees is 1000 per month (~USD 16 in
year 2012) with range of INR 0e25000; which is approximately
0e25% of per capita income. Knowledge about use of CAMwill help
to understand any drug related side effects or drug inter-actions in
the patients.Conﬂict of interest
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